Garsorasib, a KRAS G12C inhibitor, with or without cetuximab, an EGFR antibody, in colorectal cancer cohorts of a phase II trial in advanced solid tumors with KRAS G12C mutation
Authors:
Open Access
- 17 June 2025
- journal article
- research article
- Published by Springer Nature in Signal Transduction and Targeted Therapy
- Vol. 10 (1) , 1-9
Abstract
Mutations in the KRAS gene have long been implicated in the pathogenesis of colorectal cancer (CRC). KRAS G12C inhibitors overcome the “undruggable” challenge, enabling precision therapy. Garsorasib (D-1553), a highly potent and selective KRAS G12C inhibitor, has demonstrated promising anti-tumor activity and favorable safety profile in early clinical trials. We conducted an open-label, nonrandomized phase II trial (ClinicalTrials.gov, NCT04585035) to assess the safety and efficacy of garsorasib with or without cetuximab in KRAS G12C-mutated CRC. In the monotherapy cohort (n = 26), objective response rate (ORR) was 19.2% (95% CI, 6.6–39.4), disease control rate (DCR) was 92.3% (95% CI, 74.9–99.1), median progression-free survival (PFS) was 5.5 months (95% CI, 2.9–11.6) and median overall survival (OS) was 13.1 months (95% CI, 9.5-NE). In the combination cohort (n = 42), ORR was 45.2% (95% CI, 29.8–61.3), DCR was 92.9% (95% CI, 80.5–98.5), median PFS was 7.5 months (95% CI, 5.5–8.1), and median OS was not reached. Grade ≥3 treatment-related adverse events occurred in 5 (19.2%) and 6 (14.3%) patients in monotherapy and combination cohort, respectively. Garsorasib with or without cetuximab showed a promising efficacy and manageable safety profiles in heavily pretreated patients with KRAS G12C-mutated CRC, providing a potential new treatment approach for such population.Keywords
This publication has 32 references indexed in Scilit:
- Structural insights into small-molecule KRAS inhibitors for targeting KRAS mutant cancersEuropean Journal of Medicinal Chemistry, 2024
- 106P Efficacy and safety of IBI351 (GFH925) monotherapy in metastatic colorectal cancer harboring KRASG12C mutation: Updated results from a pooled analysis of two phase I studiesAnnals of Oncology, 2023
- 1622P D-1553 in patients with KRAS G12C mutated advanced pancreatic cancer (pca)Annals of Oncology, 2023
- D-1553 (Garsorasib), a Potent and Selective Inhibitor of KRASG12C in Patients With NSCLC: Phase 1 Study ResultsJournal of Thoracic Oncology, 2023
- Adagrasib: First ApprovalDrugs, 2023
- KRASG12C-independent feedback activation of wild-type RAS constrains KRASG12C inhibitor efficacyCell Reports, 2022
- Sotorasib: First ApprovalDrugs, 2021
- The Prognostic Impact of KRAS G12C Mutation in Patients with Metastatic Colorectal Cancer: A Multicenter Retrospective Observational StudyThe Oncologist, 2021
- KRAS G12C Metastatic Colorectal Cancer: Specific Features of a New Emerging Target PopulationClinical Colorectal Cancer, 2020
- Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trialThe Lancet, 2013